<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377715</url>
  </required_header>
  <id_info>
    <org_study_id>DIM02</org_study_id>
    <nct_id>NCT00377715</nct_id>
  </id_info>
  <brief_title>Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medivation, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and potential benefit of Dimebon as compared to placebo
      in patients with mild to moderate Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - cognitive subscale</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessed By Number of Participants With Adverse Events</measure>
    <time_frame>26 weeks</time_frame>
    <description>Adverse events will be assessed through physical examinations, electrocardiograms, and clinical laboratory data (chemistry panel, complete blood count (CBC) with differential, and urinalysis). The incidence of adverse events will be summarized by severity and relationship to study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter of Dimebon: Cmax</measure>
    <time_frame>Week 1, 2, 6, 12, 18, 24. Blood PK samples will be obtained pre-dose and 1 hour post-dose for each timepoint.</time_frame>
    <description>Cmax: Maximum concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Dimebon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dimebon 20 mg three times a day x 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 20 mg three times a day x 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon</intervention_name>
    <arm_group_label>Dimebon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females greater than or equal to 50 years of age.

          2. Diagnosis of Alzheimer's Disease according to Diagnostic and Statistical Manual of
             Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) and Mini Mental State Exam
             between 10 and 24, inclusive and Modified Hachinski Ischemia Score less than or equal
             to 4.

          3. Brain imaging such as MRI and/or CT within one year of enrollment.

          4. Subjects must have a guardian or caregiver who assists the subject at least 5 days per
             week (at least 3 hours/day).

          5. Subjects must be able to cooperate with drug administration (including the ability to
             ingest oral medications) and study procedures and abide by study restrictions.

          6. Subjects must have at least 6 years of prior education and should have previously (in
             pre-Alzheimer's condition) been capable of reading, writing and communicating
             effectively with others.

          7. Subjects must be willing and able to give informed consent or have a mentally
             competent legal representative authorized to provide informed consent on their behalf.

          8. Residence in an assisted care facility is allowed if subject is living independently.

        Exclusion Criteria:

          1. Major structural brain disease

          2. Major medical illness or unstable medical condition within 6 months of screening that
             may interfere with the subject's ability to comply with study procedures and abide by
             study restrictions.

          3. Residence in a nursing home or assisted care facility that provides the subject with
             24-hour care and supervision.

          4. Women who are pregnant, nursing, or if of child-bearing potential not using a
             medically accepted, highly effective method of birth control.

          5. Active alcohol dependence or drug abuse.

          6. Use of the following medications within 60 days prior to enrollment:cognition
             enhancing agents, narcotic analgesics, low potency neuroleptics, antihypertensive
             agents with frequent Central Nervous System (CNS) side effects, anti-Parkinsonian
             medications, medications with central anticholinergic activity, medications for
             epilepsy, lithium.

          7. Participation in an investigational drug or device study within 30 days prior to study
             entry, or 60 days prior to study entry if the investigational drug study involved
             therapy for Alzheimer's Disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mental Health Research Center of Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2006</study_first_submitted>
  <study_first_submitted_qc>September 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dimebon, Alzheimer's Disease, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

